2006-005978-51: Uncontrolled, multicenter, dose finding, safety and pharmacokinetic study of AVE1642, an anti-Insulin-like Growth Factor-1 Receptor (IGF-1R/ CD221) monoclonal antibody, administered as single agent and in combination with anticancer therapies in patients with advanced solid tumors |
|
|
| | 1 | 110 | Europe | NA, doxorubicin, AVE1642, Taxotere, Gemzar, Tarceva, Taxotere, Gemzar, Tarceva | sanofi-aventis recherche & développement | Advanced solid tumors | | | | |
